Advertisement

Combination Therapy In Dyslipidemia

  • Maciej Banach

Table of contents

  1. Front Matter
    Pages i-viii
  2. Peter P. Toth, Dragana Nikolic, Manfredi Rizz, Jacek Rysz, Maciej Banach
    Pages 1-10
  3. Piotr Chruściel, Dimitri P. Mikhailidis, Peter P. Toth, Jacek Rysz, Maciej Banach
    Pages 11-23
  4. Ulrich Laufs
    Pages 25-36
  5. Aris P. Agouridis, Dimitri P. Mikhailidis
    Pages 37-43
  6. Eric J. Brandt, Michael H. Davidson
    Pages 45-64
  7. Jing Pang, Dick C. Chan, Gerald F. Watts
    Pages 73-86
  8. Arrigo F. G. Cicero, Alessandro Colletti
    Pages 127-142
  9. Patrick M. Moriarty, Audrey E. McCalley
    Pages 143-152
  10. Dragana Nikolic, Niki Katsiki, Peter P. Toth, Maciej Banach, Khalid Al-Waili, Khalid Al-Rasadi et al.
    Pages 179-190
  11. Maciej Banach
    Pages 201-205

About this book

Introduction

Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia, and includes discussion of future therapies that are currently in late stages of clinical evaluation.

Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia.

Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on therapy with different agents modulating the different lipid fractions in the blood, e.g. bile acid sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP), and the emerging proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. There is additional discussion of the role of non-drug therapy options such as nutraceuticals, functional foods and lipoprotein apheresis. The book also discusses the combination of antihypertensive drugs with lipid-lowering drugs in the management of cardiovascular risk in patents with dyslipidemia.

Keywords

Alirocumab Anacetrapib Apolipoprotein B-100 inhibitors Bile acid sequestrants Bococizumab CETP inhibitors Cholesteryl ester transfer protein inhibitors Evacetrapib Evolocumab Ezetimibe Fibrates Fibric acid derivatives Fish oils Garlic HMG CoA reductase inhibitors Lomitapide MTP inhibitors Microsomal triglyceride transfer protein inhibitors Mipomersen NPC1L1 protein inhibitors Niemann-Pick C1 like 1 protein inhibitors Omega-3 fatty acids PCSK9 inhibitors Proprotein convertase subtilisin/kexin type 9 inhibitors Stanols Statins Sterols

Editors and affiliations

  • Maciej Banach
    • 1
  1. 1.Department of HypertensionWAM University Hospital in Lodz, Medical University of LodzLodzPoland

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-319-20433-8
  • Copyright Information Springer International Publishing Switzerland 2015
  • Publisher Name Adis, Cham
  • eBook Packages Medicine
  • Print ISBN 978-3-319-20432-1
  • Online ISBN 978-3-319-20433-8
  • Buy this book on publisher's site
Industry Sectors
Pharma
Health & Hospitals
Biotechnology